Drug intelligence / Profile preview

human papillomavirus type 18 L1 capsid protein antigen

Development stage
Approved
Lead developer
Merck
Modality
Vaccines & Immunotherapeutics, Recombinant Proteins and Enzymes
Administration
Intramuscular
01

Overview

Human papillomavirus type 18 L1 capsid protein antigen is a recombinant viral protein that forms the major structural component of the virus-like particles (VLPs) used in prophylactic vaccines against human papillomavirus (HPV). It is produced using recombinant DNA technology in yeast (*Saccharomyces cerevisiae*) or insect cells and self assembles into VLPs that mimic the native virus structure but lack viral DNA. These VLPs elicit a strong immune response by inducing neutralizing antibodies against oncogenic high-risk types of HPVs—primarily types 16 and 18—which are associated with cervical cancer and other anogenital cancers. The antigen is a key active ingredient in approved vaccines such as Gardasil (quadrivalent/nonavalent) and Cervarix (bivalent), which are indicated for prevention of diseases caused by infection with specific high-risk HPVs[1][7][8]. The mechanism of action involves induction of serotype-specific immunity through presentation of conformational epitopes on the surface of VLPs.

Brand names
GardasilGardasil 9Gardasil9Gardasil-9Cervarix
Other names
HPV-18 L1 proteinHPV18 L1 proteinHPV 18 L1 proteinHPV-18 Shell ProteinHPV18 Shell ProteinHPV 18 Shell ProteinHPV-18 Capsid ProteinHPV18 Capsid ProteinHPV 18 Capsid ProteinHPV-18 Coat ProteinHPV18 Coat ProteinHPV 18 Coat ProteinHPV-18 Major Capsid ProteinHPV18 Major Capsid ProteinHPV 18 Major Capsid ProteinHPV-18 Structural ProteinHPV18 Structural ProteinHPV 18 Structural ProteinHPV-18 Viral Capsid Protein L1HPV18 Viral Capsid Protein L1HPV 18 Viral Capsid Protein L1HPV-18 Outer Capsid ProteinHPV18 Outer Capsid ProteinHPV 18 Outer Capsid ProteinHPV-18 Shell Component L1HPV18 Shell Component L1HPV 18 Shell Component L1HPV-18 Capsomer Protein L1HPV18 Capsomer Protein L1HPV 18 Capsomer Protein L1HPV-18 Surface Antigen L1HPV18 Surface Antigen L1HPV 18 Surface Antigen L1
02

Targets

BCR (Immunoglobulin G B Cell Receptor)

Beyond the preview

Go deeper on human papillomavirus type 18 L1 capsid protein antigen.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on human papillomavirus type 18 L1 capsid protein antigen.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call